Catch up with some of the children with SMA Type 1 who took part in group 2 of the START clinical study of ZOLGENSMA. Hear about why they chose ZOLGENSMA and see how they are doing years after treatment.Watch their videos
What causes SMA? How does ZOLGENSMA work in the body? How do you start treatment with ZOLGENSMA? Get these answers and many more in this in-depth guide created just for caregivers.Get the guide
What is the most important information I should know about
What is the most important information I should know about ZOLGENSMA?
What should I watch for before and after infusion with ZOLGENSMA?
What do I need to know about vaccinations and ZOLGENSMA?
Do I need to take precautions with the patient’s bodily waste?
What are the possible or likely side effects of ZOLGENSMA?
What is ZOLGENSMA?
ZOLGENSMA is a prescription gene therapy used to treat children less than 2 years old with spinal muscular atrophy (SMA). ZOLGENSMA is given as a one-time infusion into a vein. ZOLGENSMA was not evaluated in patients with advanced SMA.
The safety information provided here is not comprehensive. Talk to the patient’s doctor about any side effects that bother the patient or that don’t go away.
You are encouraged to report suspected side effects by contacting the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch, or Novartis Gene Therapies, Inc. at 833-828-3947.
Please see the Full Prescribing Information.